To evaluate the immune-dependency of the observed tumor control between KCL-HO-1i and gemcitabine, MMTV-PyMT mice bearing established tumors were depleted of CD8+ T-cells prior to initiating KCL-HO-1i/gemcitabine treatment. This evidence concerns the gene CD8A and neoplasm.